<乌鸦传媒>Lung Cancer Screening Programs Hit the Mark on Eligibility Criteria However, adherence to follow-up screening is "suboptimal" Oct 10, 2022
<乌鸦传媒>More Evidence Backing Anti-CDK4/6-Based Therapy in Recurrent Endometrial Cancer Abemaciclib plus letrozole led to 30% objective response rate, 55.6% PFS rate at 6 months Oct 10, 2022
<乌鸦传媒>If You Invite 455 People to Colonoscopy, You'll Stop One Case of Cancer Risk of colorectal cancer reduced with screening in randomized trial, but less than expected Oct 09, 2022
<乌鸦传媒>Katie Couric's Breast Cancer The popular media personality is on a mission to raise awareness around dense breasts Oct 06, 2022
<乌鸦传媒>FDA's Power Morcellator Warning Tied to Drop in Distant Leiomyosarcomas Local and regional illness remained unchanged Oct 04, 2022
<乌鸦传媒>Combo Therapy Shows Promise in Advanced Thymic Epithelial Tumors "Clinically remarkable outcomes" with PD-L1 inhibitor plus anti-angiogenesis agent Oct 04, 2022
<乌鸦传媒>Pandemic Led to Surgical Delays in Gynecologic Cancers, and Worse Outcomes One in five patients experienced changes in their care plan Oct 04, 2022
<乌鸦传媒>SABR for Oligometastatic Cancer Turns in 'Acceptable' Rates of Toxicity Rates of grade 2 or higher toxicities less than those observed in landmark SABR-COMET study Oct 03, 2022
<乌鸦传媒>Adding Chemo Not Better for Recurrent Endometrial Cancer Trial suggests radiation therapy alone remains standard of care for pelvic-only recurrences Oct 03, 2022
<乌鸦传媒>Transplant With Orca-T Reduced GVHD in Hematologic Malignancies Risk of relapse was also lower in the group who received the cell therapy Oct 03, 2022
<乌鸦传媒>Durvalumab-CRT Pairing Disappoints in Locally Advanced Cervical Cancer Still, CALLA trial findings "will inform future strategies to improve treatment," researcher says Oct 02, 2022
<乌鸦传媒>ADC Offers Promising Results in Relapsed or Refractory Hodgkin Lymphoma Good response rate with camidanlumab tesirine, although a lot of patients experienced AEs Oct 02, 2022
<乌鸦传媒>Rucaparib a Winner for PFS, But Not for OS, in Recurrent Ovarian Cancer PARP inhibitor still has value as maintenance therapy, ARIEL3 investigator says Oct 01, 2022
<乌鸦传媒>'Potential Detrimental Effect' With Fourth-Line Olaparib in Ovarian Cancer Post-hoc data from SOLO3 show diverging results based on prior lines of therapy Sep 30, 2022
<乌鸦传媒>Anti-BCMA-Based Regimen Impresses in Relapsed/Refractory Myeloma Belamaf plus lenalidomide-dexamethasone achieved encouraging responses Sep 30, 2022
<乌鸦传媒>Response-Based Ponatinib Dose Reduction a Win-Win in Chronic-Phase CML? Strategy applied in OPTIC trial may mitigate adverse events without sacrificing benefit Sep 29, 2022
<乌鸦传媒>Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS About a third of patients, including those with TP53 mutations, achieved complete remission Sep 29, 2022
<乌鸦传媒>Immunotherapy First for BRAF Melanoma Edges Out Targeted Combination "Clinically meaningful" improvement in 2- and 3-year survival Sep 28, 2022
<乌鸦传媒>Was I Conned by a 'Grey's Anatomy' Writer? Her alleged duplicity could make things tougher for female patients Sep 27, 2022
<乌鸦传媒>Cancer in Kids Tied to Prenatal Exposure to High-Dose Folic Acid and Seizure Meds But no link seen among children of mothers without epilepsy Sep 26, 2022
<乌鸦传媒>'Unparalleled Times' in Hematology, but Workforce Issues Persist "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
<乌鸦传媒>What's on Tap at the Society of Hematologic Oncology's 10th Annual Meeting Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
<乌鸦传媒>FDA Grants First Tumor-Agnostic Approval for RET Fusion-Positive Cancers Selpercatinib approved for advanced or metastatic solid tumors that progress on systemic therapy Sep 22, 2022
<乌鸦传媒>How Does Oncology Deal With Pandemic Burnout? Evidence suggests the pandemic could have long-term consequences Sep 20, 2022
<乌鸦传媒>Closing Colorectal Cancer Screening Gaps With FIT Initiative VA hospital meets goal of increasing monthly screenings to address backlog from pandemic Sep 19, 2022
<乌鸦传媒>Radiation Oncology Residents Report Deficits in Training During the Pandemic About half worry about job prospects Sep 19, 2022
<乌鸦传媒>How a Dedicated Bone Marrow Biopsy Clinic Eased Wait Times VA center in Cleveland got program up and running in about a month Sep 19, 2022
<乌鸦传媒>Clinical Decision Tool Cuts Inappropriate BMA Therapy in Prostate Cancer Study at VA center shows better disease-related bone healthcare Sep 18, 2022
<乌鸦传媒>IV Iron Replacements Go Head-to-Head for IBD-Related Anemia Trial confirms higher rate of hypophosphatemia with ferric carboxymaltose Sep 16, 2022
<乌鸦传媒>Is Cancer Therapy Also a Lupus Cure? Patients in pilot study show months-long complete remission Sep 15, 2022
<乌鸦传媒>Hand Cooling, Compression Both Effective for Nerve Pain in Breast Cancer But access, cost, and tolerability may favor the latter option, said researcher Sep 14, 2022
<乌鸦传媒>Potential Practice-Changer for Refractory Metastatic Colon Cancer Significant survival gain with fruquintinib in patients with heavily pretreated disease Sep 14, 2022
<乌鸦传媒>Non-Chemo Regimen Led to High Response Rates in Cisplatin-Ineligible Bladder Cancer "Encouraging activity" with enfortumab vedotin-pembrolizumab in patients with high unmet need Sep 14, 2022
<乌鸦传媒>Long-Term ADT With Radiation Helps Prevent Post-Prostatectomy Metastases However, no benefit seen with short-term hormone therapy versus radiotherapy alone Sep 13, 2022
<乌鸦传媒>Denosumab Halts Bone Loss From Ovarian Suppression, AIs for Breast Cancer Areal BMD increased when given at the start of maximal estradiol depletion therapy Sep 13, 2022
<乌鸦传媒>Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma Large increase in event-free survival with neoadjuvant plus adjuvant versus only adjuvant therapy Sep 13, 2022
<乌鸦传媒>KRAS Inhibitor Tops Docetaxel for Previously Treated NSCLC "New second-line standard" in KRAS G12C-mutant disease, says study investigator Sep 13, 2022
<乌鸦传媒>Triplet in First-Line Kidney Cancer Thwarts Disease Progression Randomized study shows "clinically meaningful" PFS improvement over dual immunotherapy alone Sep 13, 2022
<乌鸦传媒>Survival Bump in Unfit NSCLC With First-Line Immunotherapy Atezolizumab doubles OS at 2 years versus chemotherapy in those ineligible for platinum doublets Sep 12, 2022
<乌鸦传媒>Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma Pathologic complete responses seen in 63% of patients in phase II data Sep 12, 2022
